论文部分内容阅读
目的对美托洛尔联合丹参注射液治疗乙型肝炎硬化性心肌病的临床效果进行分析和探讨。方法 90例乙型肝炎硬化性心肌病患者,随机分为观察组和对照组,各45例。对照组给予常规治疗,观察组患者在对照组基础上再接受美托洛尔联合丹参注射液治疗。对比各自的临床效果。结果观察组患者总胆红素(TBIL)、白蛋白(ALB)、丙氨酸氨基转移酶(ALT)显著优于对照组(P<0.05);治疗4周后观察组的左心室射血分数(LVEF)和舒张早期二尖瓣血流速度与舒张晚期二尖瓣血流速度比值(E/A)分别为(0.552±0.076)%、(1.339±0.122),显著优于对照组的(0.459±0.076)%、(1.022±0.113)(P<0.05)。结论美托洛尔联合丹参注射液治疗乙型肝炎硬化性心肌病的临床效果显著,疗效安全可靠,可有效缓解患者病情,提高患者生活质量,值得临床推广。
Objective To analyze and discuss the clinical effects of metoprolol combined with Salvia injection on hepatitis B sclerosing cardiomyopathy. Methods 90 cases of hepatitis B sclerosing cardiomyopathy were randomly divided into observation group and control group, 45 cases each. Patients in the observation group received metoprolol combined with Salvia miltiorrhiza injections on the basis of the control group. Contrast their respective clinical effects. Results The total bilirubin (TBIL), albumin (ALB) and alanine aminotransferase (ALT) in the observation group were significantly better than those in the control group (P <0.05). After 4 weeks of treatment, the left ventricular ejection fraction (0.552 ± 0.076)%, (1.339 ± 0.122), respectively, which were significantly better than that of the control group (0.459), and the ratio of mitral valve velocity to diastolic mitral valve velocity (LVEF) ± 0.076)%, (1.022 ± 0.113) (P <0.05). Conclusion Metoprolol combined with Salvia miltiorrhiza injection in the treatment of hepatitis B sclerosis cardiomyopathy clinical effect is significant, safe and reliable, can effectively alleviate the patient’s condition, improve patient quality of life, it is worth clinical promotion.